Celldex Therapeutics (NASDAQ:CLDX) Trading Up 8.2%

Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s stock price traded up 8.2% during trading on Tuesday . The company traded as high as $39.49 and last traded at $39.31. 630,429 shares were traded during trading, a decline of 19% from the average session volume of 779,803 shares. The stock had previously closed at $36.34.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Tuesday, June 18th. Stifel Nicolaus initiated coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 target price on the stock. Wolfe Research initiated coverage on shares of Celldex Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, July 16th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.17.

Celldex Therapeutics Trading Up 6.9 %

The stock’s 50 day moving average price is $36.48 and its 200 day moving average price is $39.14.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Sell-side analysts forecast that Celldex Therapeutics, Inc. will post -2.39 earnings per share for the current year.

Insider Transactions at Celldex Therapeutics

In related news, VP Richard M. Wright sold 46,844 shares of Celldex Therapeutics stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $33.72, for a total value of $1,579,579.68. Following the transaction, the vice president now owns 20,833 shares in the company, valued at $702,488.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Elizabeth Crowley sold 30,000 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $34.87, for a total transaction of $1,046,100.00. Following the completion of the sale, the vice president now owns 9,074 shares of the company’s stock, valued at approximately $316,410.38. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Richard M. Wright sold 46,844 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $33.72, for a total transaction of $1,579,579.68. Following the completion of the transaction, the vice president now owns 20,833 shares in the company, valued at approximately $702,488.76. The disclosure for this sale can be found here. Insiders sold a total of 266,332 shares of company stock worth $9,155,821 in the last ninety days. Insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Celldex Therapeutics

Several institutional investors have recently bought and sold shares of CLDX. Wellington Management Group LLP raised its stake in shares of Celldex Therapeutics by 19.2% in the 4th quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock valued at $256,860,000 after acquiring an additional 1,044,728 shares during the period. Vanguard Group Inc. increased its holdings in Celldex Therapeutics by 19.8% in the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after purchasing an additional 604,251 shares in the last quarter. Eventide Asset Management LLC increased its holdings in Celldex Therapeutics by 126.9% in the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock valued at $143,966,000 after purchasing an additional 2,030,013 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after purchasing an additional 2,664,915 shares during the period. Finally, Bellevue Group AG lifted its stake in shares of Celldex Therapeutics by 15.7% during the first quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock worth $117,374,000 after purchasing an additional 380,319 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.